UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts

Molecular genetics and metabolism reports, 2019-06, Vol.19, p.100454-100454, Article 100454

2019

Volltextzugriff (PDF)

Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement

Genetics in medicine, 2006-09, Vol.8 (9), p.539-548

2006

Volltextzugriff (PDF)

The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease – A systematic literature review by a European panel of experts

Molecular genetics and metabolism, 2019-03, Vol.126 (3), p.224-235

2019

Volltextzugriff (PDF)

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

Journal of medical genetics, 2018-05, Vol.55 (5), p.351-358

2018

Volltextzugriff (PDF)

The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease – A systematic literature review by a European panel of experts

Molecular genetics and metabolism, 2019-03, Vol.126 (3), p.212-223

2019

Volltextzugriff (PDF)

Fabry Disease Therapy: State-of-the-Art and Current Challenges

International journal of molecular sciences, 2020-12, Vol.22 (1), p.206

2020

Volltextzugriff (PDF)

New insights in efficacy of different ERT dosages in Fabry disease: Switch and switch-back studies data following agalsidase beta shortage. Update of systematic review

Genetics in Medicine Open, 2023, Vol.1 (1), p.100805, Article 100805

2023

Volltextzugriff (PDF)

Clinical outcomes in elderly patients receiving agalsidase alfa treatment in the Fabry Outcome Survey

Molecular genetics and metabolism, 2024-09, Vol.143 (1-2), p.108561, Article 108561

2024

Volltextzugriff (PDF)

Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry

Orphanet journal of rare diseases, 2022-06, Vol.17 (1), p.1-238, Article 238

2022

Volltextzugriff (PDF)

The management and treatment of children with Fabry disease: A United States-based perspective

Molecular genetics and metabolism, 2016-02, Vol.117 (2), p.104-113

2016

Volltextzugriff (PDF)

Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with fabry disease

Journal of the American Society of Nephrology, 2007-05, Vol.18 (5), p.1547-1557

2007

Volltextzugriff (PDF)

A systematic literature review on the health-related quality of life and economic burden of Fabry disease

Orphanet journal of rare diseases, 2024-04, Vol.19 (1), p.181-37, Article 181

2024

Volltextzugriff (PDF)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

Molecular genetics and metabolism reports, 2015-06, Vol.3 (C), p.21-27

2015

Volltextzugriff (PDF)

Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment

Orphanet journal of rare diseases, 2015-09, Vol.10 (1), p.125-125, Article 125

2015

Volltextzugriff (PDF)

Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan

Molecular genetics and metabolism, 2019-04, Vol.126 (4), p.448-459

2019

Volltextzugriff (PDF)

Long-term safety of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing extension surveillance in Japan

Molecular genetics and metabolism reports, 2024-09, Vol.40, p.101122, Article 101122

2024

Volltextzugriff (PDF)

Analysis of renal and cardiac outcomes in male participants in the Fabry Outcome Survey starting agalsidase alfa enzyme replacement therapy before and after 18 years of age

Drug design, development and therapy, 2020-01, Vol.14, p.2149-2158, Article 2149

2020

Volltextzugriff (PDF)

Agalsidase alfa: a review of its use in the management of Fabry disease

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2012-10, Vol.26 (5), p.335-354

Keating, Gillian M

2012

Volltextzugriff (PDF)

Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey

European heart journal, 2007-05, Vol.28 (10), p.1228-1235

2007

Volltextzugriff (PDF)

Rapidly progressive cognitive impairment resulting in heavy psychosocial burden in a patient with Fabry disease undergoing hemodialysis: a case report

BMC nephrology, 2024-06, Vol.25 (1), p.1-188

2024

Volltextzugriff (PDF)

Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data

Drug design, development and therapy, 2024-01, Vol.18, p.1083-1101

2024

Volltextzugriff (PDF)

Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study

Clinical therapeutics, 2020-12, Vol.42 (12), p.2321-2330.e0

2020

Volltextzugriff (PDF)

Characterization of small fiber pathology in a mouse model of Fabry disease

eLife, 2018-10, Vol.7

2018

Volltextzugriff (PDF)

Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature

Genetics in medicine, 2017-03, Vol.19 (3), p.275-282

2017

Volltextzugriff (PDF)

Successful treatment using agalsidase alfa of a patient with Fabry disease who had anaphylaxis after agalsidase beta: A case report

Northern Clinics of Istanbul, 2024-01, Vol.11 (1), p.88-90

Cakmak, Mehmet Erdem

2024

Volltextzugriff (PDF)

1 – 25 von 119

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(95)
Mit Volltextzugriff
(91)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Agalsidase Alfa
(98)
Fabry Disease
(86)
Life Sciences & Biomedicine
(84)
Science & Technology
(84)
Enzyme Replacement Therapy
(69)
Humans
(64)
Agalsidase Beta
(56)
Fabry Disease - Drug Therapy
(50)
Male
(50)
Alpha-Galactosidase - Therapeutic Use
(43)
Female
(39)
Isoenzymes - Therapeutic Use
(37)
Adult
(35)
Genetics & Heredity
(33)
Treatment Outcome
(31)
Middle Aged
(29)
Enzymes
(27)
Adolescent
(24)
Fabry Disease - Complications
(21)
Medicine, Research & Experimental
(21)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts

Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement

The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease – A systematic literature review by a European panel of experts

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease – A systematic literature review by a European panel of experts

Fabry Disease Therapy: State-of-the-Art and Current Challenges

New insights in efficacy of different ERT dosages in Fabry disease: Switch and switch-back studies data following agalsidase beta shortage. Update of systematic review

Clinical outcomes in elderly patients receiving agalsidase alfa treatment in the Fabry Outcome Survey

Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry

The management and treatment of children with Fabry disease: A United States-based perspective

Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with fabry disease

A systematic literature review on the health-related quality of life and economic burden of Fabry disease

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment

Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan

Long-term safety of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing extension surveillance in Japan

Analysis of renal and cardiac outcomes in male participants in the Fabry Outcome Survey starting agalsidase alfa enzyme replacement therapy before and after 18 years of age

Agalsidase alfa: a review of its use in the management of Fabry disease

Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey

Rapidly progressive cognitive impairment resulting in heavy psychosocial burden in a patient with Fabry disease undergoing hemodialysis: a case report

Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data

Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study

Characterization of small fiber pathology in a mouse model of Fabry disease

Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature

Successful treatment using agalsidase alfa of a patient with Fabry disease who had anaphylaxis after agalsidase beta: A case report

Suchergebnisse filtern